{"doi":"10.1101/2025.07.05.663311","title":"Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model","abstract":"Abstract Monensin ( MON ) is a polyether ionophore antibiotic of natural origin and is an FDA-approved drug for veterinary use. Recent studies have highlighted its potential anti-cancer activity in various in vitro and in vivo models. In this study, we evaluated the anti-breast cancer activity of MON and 37 synthetic analog compounds using cell monolayer and organoid models. Through a mini-ring cell viability assay, several compounds were identified that were more potent and selective against breast cancer cells compared to non-cancerous cells, surpassing the activity of parent MON . MON and these compounds induced significant DNA fragmentation, reduced cell migration, and downregulated SOX2 expression. Furthermore, MON and the most potent analog, compound 12 , reduced the percentage of CD44 + /CD24 -/low stem-like cells and diminished cell self-renewal properties. Proteomics analyses revealed that several pathways, including extracellular matrix organization, were significantly dysregulated by MON and compound 12 in breast cancer cells. Among these, TIMP2, a protein associated with the suppression of tumor growth and metastasis, was identified as one of the most prominently upregulated proteins by MON and compound 12 in MDA-MB-231 cells. This finding was also validated in other breast cancer and melanoma cell lines. To simulate breast cancer metastasis to the brain, a human Hybrid Organoid System: Tumor in Brain Organoid (HOSTBO) model was developed. MON and compound 12 significantly reduced Ki-67 expression within the HOSTBOs, and compound 12 significantly downregulated SOX2 expression. Collectively, MON and compound 12 significantly reduced the proliferation of breast cancer stem-like cells in the organoid models, inhibited their migration, and dysregulated markers associated with stemness, demonstrating their potential as anti-metastatic agents and warranting further clinical development. Abstract Figure","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2025,"id":569971,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9603,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":894135,"name":"Billie Heflin","orcid":"0000-0001-8774-4579","position":1,"is_corresponding":false},{"id":308652,"name":"Eric R. Siegel","orcid":"0000-0001-9824-6612","position":2,"is_corresponding":false},{"id":570240,"name":"Megan R. Reed","orcid":"0000-0001-5086-7938","position":3,"is_corresponding":false},{"id":1305761,"name":"J. Stephen Nix","orcid":"0000-0001-5386-3617","position":4,"is_corresponding":false},{"id":406870,"name":"Eric U. Yee","orcid":"0000-0001-9643-6439","position":5,"is_corresponding":false},{"id":894136,"name":"Marta Jędrzejczyk","orcid":"0000-0003-4214-569X","position":6,"is_corresponding":false},{"id":894137,"name":"Greta Klejborowska","orcid":"0000-0001-9365-4238","position":7,"is_corresponding":false},{"id":894626,"name":"Natalia Stępczyńska","orcid":null,"position":8,"is_corresponding":false},{"id":894139,"name":"Adam Huczyński","orcid":"0000-0003-4770-215X","position":9,"is_corresponding":false},{"id":1475447,"name":"Marius B. Nagalo","orcid":null,"position":10,"is_corresponding":false},{"id":894138,"name":"Timothy C. Chambers","orcid":"0000-0002-3122-9794","position":11,"is_corresponding":false},{"id":556148,"name":"Steven R. Post","orcid":"0000-0002-4711-1723","position":12,"is_corresponding":false},{"id":391330,"name":"Robert L. Eoff","orcid":"0000-0003-4776-8925","position":13,"is_corresponding":false},{"id":245209,"name":"Melanie C MacNicol","orcid":"0000-0001-6927-2475","position":14,"is_corresponding":false},{"id":339537,"name":"Amit K. Tiwari","orcid":"0000-0002-7427-7155","position":15,"is_corresponding":false},{"id":665224,"name":"Thomas J. Kelly","orcid":"0000-0001-5781-0619","position":16,"is_corresponding":false},{"id":379499,"name":"Alan J. Tackett","orcid":"0000-0002-3672-4460","position":17,"is_corresponding":false},{"id":245210,"name":"Angus M. MacNicol","orcid":"0000-0003-4812-9519","position":18,"is_corresponding":false},{"id":743281,"name":"Alicja Urbaniak","orcid":"0000-0002-0807-1263","position":0,"is_corresponding":true}],"reference_count":76,"raw_metadata":null,"created_at":"2026-07-19T02:57:03.510013Z","pmid":"40672259","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}